Mutant KEAP 1 is present in non-small-cell lung cancer (NSCLC) cell lines and in NSCLC patients, which leads to constitutive activation of Nrf2 function and cytoprotection against ROS-generating radiotherapy and chemotherapeutic agents [13]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.